Tick-Borne Encephalitis Virus, NS1 (Clone TBEV-5011)

Culture virus infected cell lysate; Neudoerfl strain

Formulated in 0.015 M phosphate buffered saline (0.85% NaCl), pH 7.2 and contains 0.05% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

This monoclonal antibody is purified by ion exchange chromatography.

This purified antibody is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2 – 8° C Wet Ice

Anti-Tick-Borne Encephalitis Virus (Clone TBEV-5011) is specific for the non-structural protein 1 (NS1) from Tick-Borne Encephalitis Virus. There is no cross-reactivity with other Flavivirus.

Tick-borne encephalitis virus (TBEV) is a single-stranded RNA virus that is a member of the Flaviviridae family within the genus Flavivirus. The virus is primarily transmitted to humans through the bite of infected ticks, with Ixodes ricinus and Ixodes persulcatus being the main vectors. TBEV is categorized into three subtypes: European, Siberian, and Far Eastern. The virus causes tick-borne encephalitis (TBE), a viral neurological disease characterized by fever, headache, and, in severe cases, inflammation of the brain. The disease burden of TBE varies geographically, with endemic regions in parts of Europe, Asia, and Russia. TBE poses a significant public health concern, and vaccination campaigns have been implemented in endemic areas to mitigate the impact of this potentially severe and sometimes fatal disease. References:

1. Hills SL, Poehling KA, Chen WH, Staples JE. Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep 2023;72(No. RR-5):1–29.